
John J Sim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2134541/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Rates of Biopsy-Proven Pediatric Glomerulopathies in a Large Health System, 2000-2014. American Journal of Kidney Diseases, 2022, 79, 453-455.	2.1	2
2	Potentially Harmful Medication Dispenses After a Fall or Hip Fracture: A Mixed Methods Study of a Commonly Used Quality Measure. Joint Commission Journal on Quality and Patient Safety, 2022, , .	0.4	0
3	Causes of Death in End-Stage Kidney Disease: Comparison between the United States Renal Data System and a Large Integrated Health Care System. American Journal of Nephrology, 2022, 53, 32-40.	1.4	9
4	Antibiotic practice patterns with procalcitonin levels in patients with acute lower respiratory tract infection. American Journal of Managed Care, 2022, 28, e35-e41.	0.8	0
5	Statin Use and Mortality among Patients Hospitalized with Sepsis: A Retrospective Cohort Study within Southern California, 2008–2018. Critical Care Research and Practice, 2022, 2022, 1-7.	0.4	1
6	COVID-19 and Survival in Maintenance Dialysis. Kidney Medicine, 2021, 3, 132-135.	1.0	27
7	β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis. American Journal of Kidney Diseases, 2021, 77, 704-712.	2.1	12
8	Angiotensinâ€Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVIDâ€19 Infection Among 824Â650 Patients With Hypertension From a US Integrated Healthcare System. Journal of the American Heart Association, 2021, 10, e019669.	1.6	26
9	Statin use and survival among ESKD patients hospitalized with sepsis. CKJ: Clinical Kidney Journal, 2021, 14, 1710-1712.	1.4	3
10	COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare system. International Journal of Cardiology: Hypertension, 2021, 9, 100088.	2.2	4
11	Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease. Pharmacotherapy, 2021, 41, 998-1008.	1.2	10
12	Autosomal Dominant Polycystic Kidney Disease Prevalence among a Racially Diverse United States Population, 2002 through 2018. Kidney360, 2021, 2, 2010-2015.	0.9	18
13	Subâ€∎cute hyponatraemia more than chronic hyponatraemia is associated with serious falls and hip fractures. Internal Medicine Journal, 2020, 50, 1100-1108.	0.5	6
14	A Comparison of Death Records Between the United States Renal Data System and a Large Integrated Health Care System. Kidney International Reports, 2020, 5, 912-915.	0.4	2
15	Apparent treatment-resistant hypertension: characteristics and prevalence in a real-world environment of an integrated health system. Journal of Hypertension, 2020, 38, 1603-1611.	0.3	10
16	Association between hypothyroidism and chronic kidney disease observed among an adult population 55 years and older. Medicine (United States), 2020, 99, e19569.	0.4	13
17	Identifying Patients with Rare Disease Using Electronic Health Record Data: The Kaiser Permanente Southern California Membranous Nephropathy Cohort. , 2020, 24, .		13
18	Follow-up of Abnormal Estimated GFR Results Within a Large Integrated Health Care Delivery System: A Mixed-Methods Study. American Journal of Kidney Diseases, 2019, 74, 589-600.	2.1	10

Јони Ј Ѕім

#	Article	IF	CITATIONS
19	Patients with Idiopathic Membranous Nephropathy: A Real-World Clinical and Economic Analysis of U.S. Claims Data. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 1011-1020.	0.5	9
20	The Kaiser Permanente Los Angeles Annual Research Week Abstracts. , 2019, 23, .		0
21	Betaâ€blocker practice patterns in chronic kidney disease patients with atrial fibrillation transitioning to hemodialysis. Hemodialysis International, 2019, 23, 506-509.	0.4	1
22	US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States. American Journal of Kidney Diseases, 2019, 73, A7-A8.	2.1	680
23	Early Mortality Among Peritoneal Dialysis and Hemodialysis Patients Who Transitioned With an Optimal OutpatientÂStart. Kidney International Reports, 2019, 4, 275-284.	0.4	14
24	Association of thyroid status prior to transition to end-stage renal disease with early dialysis mortality. Nephrology Dialysis Transplantation, 2019, 34, 2095-2104.	0.4	20
25	End-Stage Renal Disease and Mortality Outcomes Across Different Clomerulonephropathies in a Large Diverse US Population. Mayo Clinic Proceedings, 2018, 93, 167-178.	1.4	29
26	Disparities in early mortality among chronic kidney disease patients who transition to peritoneal dialysis and hemodialysis with and without catheters. International Urology and Nephrology, 2018, 50, 963-971.	0.6	22
27	Intradialytic hypotension, blood pressure changes and mortality risk in incident hemodialysis patients. Nephrology Dialysis Transplantation, 2018, 33, 149-159.	0.4	110
28	In Reply—End-Stage Renal Disease Risk in Different Glomerulonephropathies. Mayo Clinic Proceedings, 2018, 93, 959-960.	1.4	0
29	Low Systolic Blood Pressure From Treatment and Association With Serious Falls/Syncope. American Journal of Preventive Medicine, 2018, 55, 488-496.	1.6	28
30	Blood Pressure Before Initiation of Maintenance Dialysis and Subsequent Mortality. American Journal of Kidney Diseases, 2017, 70, 207-217.	2.1	28
31	US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States. American Journal of Kidney Diseases, 2017, 69, A7-A8.	2.1	716
32	Use of Phosphorus Binders among Non-Dialysis Chronic Kidney Disease Patients and Mortality Outcomes. American Journal of Nephrology, 2017, 45, 431-441.	1.4	6
33	Transition of care from pre-dialysis prelude to renal replacement therapy: the blueprints of emerging research in advanced chronic kidney disease. Nephrology Dialysis Transplantation, 2017, 32, ii91-ii98.	0.4	71
34	Characteristics of patients diagnosed with renal vein thrombosis and glomerulopathy: a case series. International Urology and Nephrology, 2017, 49, 285-293.	0.6	4
35	End-Stage Renal Disease Outcomes among the Kaiser Permanente Southern California Creatinine Safety Program (Creatinine SureNet): Opportunities to Reflect and Improve. , 2017, 21, 16-143.		11
36	Focal Segmental Glomerulosclerosis in a Patient with Ambiguous Genitalia: A Diagnostic Dilemma. , 2017, 21, 16-092.		0

Јони Ј Ѕім

#	Article	IF	CITATIONS
37	Serum sodium and mortality in a national peritoneal dialysis cohort. Nephrology Dialysis Transplantation, 2016, 32, gfw254.	0.4	20
38	Short-Term Risk of Serious Fall Injuries in Older Adults Initiating and Intensifying Treatment With Antihypertensive Medication. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 222-229.	0.9	64
39	Distribution of Biopsy-Proven Presumed Primary Glomerulonephropathies in 2000-2011 Among a Racially and Ethnically Diverse US Population. American Journal of Kidney Diseases, 2016, 68, 533-544.	2.1	83
40	Plasma renin activity and risk of cardiovascular and mortality outcomes among individuals with elevated and nonelevated blood pressure. Kidney Research and Clinical Practice, 2016, 35, 219-228.	0.9	13
41	Comparisons of sleep apnoea rate and outcomes among patients with resistant and nonâ€resistant hypertension. Respirology, 2016, 21, 1486-1492.	1.3	12
42	Patient-Reported Factors Associated With Poor Phosphorus Control in a Maintenance Hemodialysis Population. , 2016, 26, 141-148.		10
43	US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. American Journal of Kidney Diseases, 2016, 67, A7-A8.	2.1	440
44	Serum phosphorus and association with anemia among a large diverse population with and without chronic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 636-645.	0.4	31
45	Changes in Pulse Pressure during Hemodialysis Treatment and Survival in Maintenance Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1179-1191.	2.2	22
46	Kaiser Permanente Creatinine Safety Program: AÂMechanism to Ensure Widespread Detection andÂCare for Chronic Kidney Disease. American Journal of Medicine, 2015, 128, 1204-1211.e1.	0.6	28
47	Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney International, 2015, 88, 622-632.	2.6	146
48	The Utility of Ambulatory Blood Pressure Monitoring for Diagnosing White Coat Hypertension in Older Adults. Current Hypertension Reports, 2015, 17, 86.	1.5	9
49	Plasma Renin Activity and Its Association With Ischemic Heart Disease, Congestive Heart Failure, and Cerebrovascular Disease in a Large Hypertensive Cohort. Journal of Clinical Hypertension, 2014, 16, 805-813.	1.0	8
50	Impact of Achieved Blood Pressures onÂMortality Risk and End-Stage RenalÂDisease Among a Large, DiverseÂHypertension Population. Journal of the American College of Cardiology, 2014, 64, 588-597.	1.2	138
51	Systemic Implementation Strategies to Improve Hypertension: The Kaiser Permanente Southern California Experience. Canadian Journal of Cardiology, 2014, 30, 544-552.	0.8	89
52	Blood Pressure and Mortality in U.S. Veterans With Chronic Kidney Disease. Annals of Internal Medicine, 2013, 159, 233.	2.0	182
53	Characteristics of Resistant Hypertension in a Large, Ethnically Diverse Hypertension Population of an Integrated Health System. Mayo Clinic Proceedings, 2013, 88, 1099-1107.	1.4	161
54	Phosphorus and Risk of Renal Failure in Subjects with Normal Renal Function. American Journal of Medicine, 2013, 126, 311-318.	0.6	65

Јони Ј Ѕім

#	Article	IF	CITATIONS
55	Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients. Kidney International Supplements, 2013, 3, 462-468.	4.6	34
56	Plasma Renin Activity (PRA) Levels and Antihypertensive Drug Use in a Large Healthcare System. American Journal of Hypertension, 2012, 25, 379-388.	1.0	24
57	Positive relationship of sleep apnea to hyperaldosteronism in an ethnically diverse population. Journal of Hypertension, 2011, 29, 1553-1559.	0.3	48
58	Association of plasma renin activity and aldosterone–renin ratio with prevalence of chronic kidney disease. Journal of Hypertension, 2011, 29, 2226-2235.	0.3	25
59	25â€Hydroxyvitamin D Levels and Hypertension Rates. Journal of Clinical Hypertension, 2011, 13, 170-177.	1.0	47
60	Dietary Omega-3 Fatty Acid, Ratio of Omega-6 to Omega-3 Intake, Inflammation, and Survival in Long-term Hemodialysis Patients. American Journal of Kidney Diseases, 2011, 58, 248-256.	2.1	59
61	Indinavir-induced nephrolithiasis three and one-half years after cessation of indinavir therapy. International Urology and Nephrology, 2011, 43, 571-573.	0.6	14
62	Vitamin D deficiency and anemia: a cross-sectional study. Annals of Hematology, 2010, 89, 447-452.	0.8	158
63	Review article: Managing sleep apnoea in kidney diseases. Nephrology, 2010, 15, 146-152.	0.7	31
64	Sleep Apnea in Early and Advanced Chronic Kidney Disease. Chest, 2009, 135, 710-716.	0.4	81
65	Sleep Apnea and Hypertension: Prevalence in Chronic Kidney Disease. Journal of Clinical Hypertension, 2007, 9, 837-341.	1.0	11
66	Prevalence of Nondiabetic Renal Disease in Diabetic Patients. American Journal of Nephrology, 2007, 27, 322-328.	1.4	144